Net Income

A new partnership tackles the rising financial threat of cognitive decline, helping Canadians protect their family, finances, and future from a growing crisis.

Autoimmune diagnostics firm Exagen reports a 12% revenue jump and improved efficiency, fueling analyst optimism and setting a strong tone for 2026.

Freshly rebranded Keel Infrastructure posts huge Q1 losses, but a $533M war chest and a 2.2GW pipeline show its real focus: the AI data center boom.

A new report says the key to consumer action isn't emotion, but the brain's background 'noise.' This finding could upend the entire advertising industry.

Olaplex posts a Q1 sales gain but a net loss in its last report before its $1.4B acquisition by Henkel, revealing shifting retail dynamics.

A new drug targeting the root cause of sebum production shows promise in clinical trials, offering hope for millions of moderate to severe acne sufferers.

Actuate Therapeutics gets FDA nod for its oral cancer drug elraglusib, shifting strategy to improve patient outcomes and tackle hard-to-treat tumors.

A massive investment in Evolution Metals aims to break China's grip on critical materials, powering US green tech and national security ambitions.

Despite lower attendance, United Parks & Resorts sees record guest spending and doubles down on new attractions and massive share buybacks.

CGBD resets its dividend amid market volatility, betting on joint ventures and wider spreads for future growth. Is this a smart move for long-term stability?

Formula 1 meets pet couture as VETRESKA partners with Ollie Bearman, signaling a new era of lifestyle brand sponsorships in high-speed motorsport.

On its 55th anniversary, discover how a Dallas restaurateur's ingenious hack of a Slurpee machine created a global cocktail craze and an American icon.

The appointment of Dr. Samyoung Chung to KIC's board places him in a unique position to influence South Korea's three largest public investment funds.

Amid financial restatements and market volatility, Genie Energy's upcoming Q1 report will be a key test of its retail and renewable energy strategies.

The specialty manufacturer reports a 46% profit surge, fueled by strong demand for its key drug and a major distributor's comeback. What's next?

The former solar EV pioneer has completed its radical pivot, selling its solar business to management and betting its entire future on Bitcoin.

Butterfly Network adds B. Braun veteran Caroll Neubauer to its board, a strategic move to leverage his global scaling and policy expertise for growth.

Continuum AI launches a free, open-source router for 200+ models, betting its future not on tolls but on enterprise-grade control and governance.

The federal tech firm posts a 23% revenue jump, eliminates debt, and builds a record backlog, signaling a new phase of strategic growth.

With two pivotal trial readouts looming and cash projected to last only into Q4, Tvardi Therapeutics faces a make-or-break year for its STAT3 inhibitors.